|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2002-3-18
|
|
pubmed:abstractText |
Gatifloxacin (GAT) and moxifloxacin (MXF) were evaluated in vitro to determine their activities against Mycobacterium tuberculosis. GAT was subsequently compared in a dose range study to isoniazid (INH) in a murine tuberculosis model. GAT was somewhat less active than INH. GAT and MXF were evaluated in mice infected with M. tuberculosis and were found to have similar activities. GAT was studied alone and in combination with ethambutol, ethionamide (ETA), and pyrazinamide (PZA) and compared to INH and rifampin (RIF). GAT appears to have sufficient activity alone and in combination with ETA with or without PZA to merit evaluation for treatment of tuberculosis.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/11897584-10049284,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11897584-10067058,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11897584-10511409,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11897584-10864193,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11897584-10952625,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11897584-11217874,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11897584-11282270,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11897584-11408228,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11897584-4073865,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11897584-7768610,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11897584-7979275,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11897584-9033176,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11897584-9462443,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11897584-9687408,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11897584-9797236,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11897584-9869570
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0066-4804
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
46
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1022-5
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:11897584-Animals,
pubmed-meshheading:11897584-Anti-Infective Agents,
pubmed-meshheading:11897584-Antitubercular Agents,
pubmed-meshheading:11897584-Aza Compounds,
pubmed-meshheading:11897584-Colony Count, Microbial,
pubmed-meshheading:11897584-Drug Combinations,
pubmed-meshheading:11897584-Female,
pubmed-meshheading:11897584-Fluoroquinolones,
pubmed-meshheading:11897584-Humans,
pubmed-meshheading:11897584-Isoniazid,
pubmed-meshheading:11897584-Mice,
pubmed-meshheading:11897584-Mice, Inbred C57BL,
pubmed-meshheading:11897584-Microbial Sensitivity Tests,
pubmed-meshheading:11897584-Mycobacterium tuberculosis,
pubmed-meshheading:11897584-Nasal Cavity,
pubmed-meshheading:11897584-Quinolines,
pubmed-meshheading:11897584-Tuberculosis
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis.
|
|
pubmed:affiliation |
Department of Microbiology and Immunology, Upstate Medical University, State University of New York, Syracuse, New York, USA.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, U.S. Gov't, P.H.S.,
Research Support, U.S. Gov't, Non-P.H.S.
|
